anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Antibiotic compsn. contains the lysine salt of cephalexin (7-(D-alpha-amino-alpha-phenylacetamido)-3-methyl-3-cephem-4-carb- oxylic acid) of formula (I) which is water soluble and may be administered by intramuscular or intravenous injection as well as orally. Cephalexin is insoluble in water and is well absorbed when administered orally. It is used to treat infections, especially those of the respiratory and urinary tracts, and is used prophylactically for post-operative infections. When the sodium or potassium salt is administered by injection it causes local pain and is poorly absorbed. This poor absorption has led to the use of other antibiotics, e.g cephaloridine for the initial parenteral treatment of acute infections followed later by the oral administration of cephalexin. This use of two different antibiotics, is inconvenient and antagonism occurs between them. The use of (I) which is well absorbed parenterally as well as orally overcomes these problems. The recommended intramuscular doses of (I) are 2-4g per day for adults, adn 30-50 mg/kg/day (rising to 100 mg/kg/day for serious infections) for children. (I) is a yellowish-white powder, m. pt 168-174 degrees C which dissolves in water to give a clear, yellow solution and is insoluble in ether and other non-polar solvents. (I) has LD50 in rats of 6g/kg s. c or i. p and in guinea pigs, 3-6g/kg s. c and 3g/kg i.p.
FIELD: peptide derivatives. SUBSTANCE: product: hexapeptide of the formula D-Ala-D-Ala-L-Tyr-D-Ala-Gly-L-Phe-NH,. Synthesis of hexapeptide is carried out under conditions of solid-phase method by gradual peptode chain splicing from tert.-butylhydroxycarbonyl-L-Phe linked with polymeric carrier Sephadex LH-20. Synthesized hexapeptide shows low toxicity ((LD= 1310 mg/kg) 1310 mg/kg) and prolonged hypertension effect as compared with angiotensin II (by 22 times) with complete absence of by-side effects. Effect of hexapeptide is displayed at intravenuos administration while that of known agent only at injection into definite brain regions. EFFECT: enhanced effectiveness of product. 1 tbl
Efficacy studies of LEUKINE could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons. The use of LEUKINE in the H-ARS indication was based on efficacy studies conducted in animals and data supporting LEUKINE’s effect on severe neutropenia in patients undergoing autologous or allogeneic BMT following myelosuppressive chemotherapy with or without total body irradiation, and in patients with acute myelogenous leukemia following myelosuppressive chemotherapy [see Dosage and Administration (2.1 to 2.6)].

The recommended dose of LEUKINE for adults exposed to myelosuppressive doses of radiation is 7 mcg/kg as a single daily SC injection [see Dosage and Administration (2.6)]. The 7 mcg/kg dosing regimen is based on population modeling and simulation analyses. The sargramostim exposure associated with the 7 mcg/kg adult dose is expected to be higher than sargramostim exposure in the nonclinical efficacy study and therefore are expected to provide sufficient pharmacodynamic activity to treat humans exposed to myelosuppressive doses of radiation [see Clinical Pharmacology (12.3)]. The safety of LEUKINE at a dose of 250 mcg/m2/day (approximately 7 mcg/kg) has been assessed on the basis of clinical experience in myeloid reconstitution in patients after autologous or allogeneic BMT, and in patients with AML [see Adverse Reactions (6.1)].

The efficacy of LEUKINE was studied in a randomized, blinded, placebo-controlled study in a nonhuman primate model of radiation injury. Rhesus macaques (50% male) were randomized to a control (n = 36) or treated (n = 36) group. Animals were exposed to total body irradiation at a dose that would be lethal in 50% to 60% of animals (655 cGy) by day 60 post irradiation (lethal dose [LD]50-60/60). Starting 48 ± 1 hour after irradiation, animals received daily SC injections of placebo (sterile water for injection, USP) or LEUKINE (7 mcg/kg/day). Blinded treatment was stopped when one of the following criteria was met: ANC ≥1,000 cells/mm3 for 3 consecutive days or if the ANC ≥10,000 cells/mm3. Animals received minimal supportive care that included a prophylactic antibiotic, antiemetic, analgesics, and parenteral fluids. No whole blood, blood products or individualized antibiotics were provided.

LEUKINE significantly (p=0.0018) increased survival at day 60 in irradiated nonhuman primates: 78% survival (28/36) in the LEUKINE group compared to 42% survival (15/36) in the control group.

In the same study, an exploratory cohort of 36 rhesus macaques randomized to control (n=18) or treated (n=18) was exposed to total body irradiation at a dose that would be lethal in 70-80% of animals (713 cGY) by day 60 post irradiation. LEUKINE increased survival at day 60 in irradiated nonhuman primates: 61% survival (11/18) in the LEUKINE group compared to 17% survival (3/18) in the control group.
Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if \<85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
Patients randomized to Group 2 will receive low literacy, written materials about HCV screening in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in patients with elevated LFTs and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody test. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will call to this potential subject. Patients will also receive centralized patient navigation to facilitate screening completion and appropriate test follow-up. He/she will help patients schedule HCV antibody testing and will assume responsibility for tracking results. Patients referred to the Hepatitis C clinic for treatment evaluation will receive reminder calls from trained and credentialed study staff 5-7 business days for scheduled appointments.
Type-2 diabetes mellitus is a public health concern. According to the World health organization (WHO), diabetes mellitus affects more than 180 million people worldwide. Type 2 diabetes mellitus accounts for 80-95% of diabetes cases in developed countries and a higher proportion in developing countries (IDF 2006). Patients with type 2 diabetes mellitus are at high risk of developing cardiovascular complications. Diabetic patients are two to four-times more likely to develope cardiovascular disease. The mortality of diabetic patients with cardiovascular disease is much higher than in non-diabetic matched patients with cardiovascular disease. Recently, it has become apparent that not all anti-diabetic drugs have the same effect on the progression of atherosclerosis and on cardiovascular outcomes. There is a great need to understand the potential protective mechanisms of the various anti-diabetic drugs in order to decrease their risk for cardiovascular morbidity and mortality. In addition to increasing insulin sensitivity, Pioglitazone (PIO) has anti-inflammatory properties. Several studies have suggested that PIO decreases serum markers of inflammation including C-reactive protein (CRP). However, the underlying mechanisms of these anti-inflammatory (and probably anti-atherosclerotic) effects of PIO are unknown. We have shown in the rat that 3-day pretreatment with PIO increases myocardial cyclooxygenase-2 (COX2) activity and levels of both 6-keto-PGF1a, the stable metabolite of prostacyclin (PGI2) and 15-epi-lipoxin A4, a lipid mediator with a strong anti-inflammatory properties. Prostacyclin inhibits platelet aggregation and causes vasodilatation. Increased levels of 6-keto-PGF1a and 15-epi-lipoxin A4 may thus be the explanation for the anti-inflammatory and anti-atherosclerosis effects of PIO. Several clinical studies have shown that COX2 inhibition is associated with increased cardiovascular events. Thus, augmenting COX2 activity and the production of prostacyclin and 15-epi-lipoxin A4 may have potential favorable effects. The purpose of the study is to test whether PIO therapy is associated with an increase in serum and/or urine levels of 6-keto-PGF1a and 15-epi-lipoxin A4 in patients with diabetes mellitus type 2.
This study will evaluate the recovery from copperhead snake bite in patients with mild or moderate venom effect. Potential subjects will receive CroFab antivenom or placebo. The trial is conducted by emergency room doctors, toxicologists, or surgeons at hospitals in regions where copperhead bites are common. After blinded treatment and discharge, the subject returns to the clinic for follow-up assessments at day 3, 7, 14, and 28 after snake bite. The subject will also be called by telephone for follow-up assessments on day 10, 17, and 24 after snake bite. The purpose of this study is to compare recovery in copperhead snake bite patients treated with antivenom vs placebo (no active drug) as measured by the Patient Specific Functional Scale (PSFS) at Day 14 follow-up.The primary efficacy endpoint of this study was achieved. Treatment with CroFab® demonstrated measurable and significant improvement (less disability) over placebo: in the mITT population, the LS mean total score on the PSFS at Day 14 follow-up and treatment showed less disability in patients randomized to receive CroFab® than those receiving placebo.
Abstract Imidazodiazepine derivatives of the general formula             I     wherein A together with the two carbon atoms denoted as .alpha. and .beta. represents one of the groups               and     (a)        (b)                  (c) and the dotted line represents the double bond present in groups (a) and (b),  D represents ?C=0 or ?C=S, R1 represents cyano, lower alkanoyl or a group of the formula -COOR4, R4  represents methyl, ethyl, isopropyl or 2-hydroxyethyl, R5 represents hydrogen, trifluoromethyl or halogen and R6 represents hydrogen, trifluoro-methyl, halogen or lower alkyl and either R2 represents hydrogen and R3 represents hydro-gen  or lower alkyl or R2 and R3 together represent trimethylene or propenylene and the carbon atom denoted as .gamma. has the S- or R,S-configuration, and pharmaceutically acceptable salts thereof are novel and are suitable for antagonising the central--depressant, muscle relaxant, ataxic, blood pressure--lowering and respiratory-depressant properties of 1,4--benzodiazepines which have tranquillising activity.          They can be used, for example, as antidotes in the case of intoxications in which excessive intake of 1,4-benzo-diazepines which have tranquillising activity par-ticipates,  for shortening an anaesthesia induced by such 1,4-benzodiazepines etc.  They can also be used for suppressing the activities on the central nervous system of 1,4-benzodiazepines used in other fields of indication, for example of schistosomicidally-active 1,4-benzodiazepines such as (+)-5-(o-chlorophenyl)-1,3-dihydro-3-methyl-7--nitro-2H-1,4-benzodiazepin-2-one.     The present imidazodiazepine derivatives can be manufactured according to various methods starting from partially novel starting materials and can be formulated into galenical administration forms.
Heart failure is a leading cause of hospital readmission. It results in significant mortality, morbidity, and health care utilization. Effective continuous remote patient monitoring (CRPM) can reduce readmissions, but it has only been realized via invasive monitoring. The study will focus on non-invasive heart failure CRPM through a structured cascading and escalating alert system. In this feasibility study, the study team will use a wearable biosensor and collect ambulatory physiological data that are analyzed by machine learning algorithms, potentially identifying physiological perturbation in heart failure patients. Alerts from this algorithm may be cascaded with other patient status data to inform management by the home health team via a structured protocol. The escalation pathway will engage home health, advanced practitioner providers, and heart failure specialists. In the first aim, the study team will perform a soft launch on five patients with an extensive evaluation to assess feasibility for the pilot trial. In aim 2, the study team will implement the feasibility pilot study. In aim 2a, the study team will conduct surveys and semi-structured interviews with both providers and patients. The surveys and interviews will be applied at three time points (initiation, maintenance, and post-study) to evaluate perceptions, acceptance, and experience of this CRPM solution. In aim 2b, the investigators will leverage temporal data mining, feature extraction, and patient clustering methods to identify valid patterns associated with the pathophysiological events of interest, using continuous physiological data, patient reports, and electronic health record data. The study team will also compare outcome and process measures from our pilot study to a retrospective cohort matched for key demographics and disease severity. This feasibility study will provide key learning for a larger efficacy clinical trial to evaluate if this non-invasive telemonitoring solution tied to structured patient management via cascading and escalating alert pathways can improve outcomes and reduce heart failure readmission.
PURPOSE:To obtain a new compound, capable of exhibiting ultraviolet ray absorbing action over a wide wavelength region and useful as ultraviolet ray absorbers, cosmetics, etc. CONSTITUTION:A compound expressed by formula I [R is 1-8C alkyl, 6-10C aryl, OH, 1-8C alkoxy, 2-8C alkenyloxy, 1-8C perfluoroalkyl, etc.; (n) and (m) are 0-4; (n+m) is >=1], e.g. 2-(3,4-dimethoxyphenyl)-6-phenyl-4H-pyran-4-one. Furthermore, the aforementioned compound expressed by formula I is obtained by condensing a benzoylacetone derivative expressed by formula II with a benzoic acid derivative expressed by formula III in the presence of a base such as sodium hydroxide as a catalyst in an aprotic solvent such as diethyl ether at 20-150 deg.C and then cyclodehyrating the resultant compound expressed by formula IV with a strong acid such as sulfuric acid. A cosmetic containing the above-mentioned compound is excellent in anti-suntan effects.
Objective: The purpose of this study was to investigate the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of chemotherapy-induced nausea and vomiting (CINV) for hematopoietic cell transplantation (HCT) patients receiving BEAM therapy. Study Design: This phase II, prospective, intention-to-treat, single-center, single-arm study involved 43 adult patients who received NEPA and dexamethasone for the prevention of CINV due to BEAM conditioning chemotherapy. An interim analysis, performed after 13 patients, determined utility versus futility, and supported continuation to full enrollment. Descriptive statistics were used to report complete response (CR), complete protection, incidence of emesis, and administration of rescue agents. A Kaplan-Meier curve depicted time to first emesis and first rescue medication. Patients self-reported levels of daily nausea descriptively via a CINV Questionnaire. Results: By study end, 13 of 43 patients achieved a CR with an average of 10.6 emesis-free days (SD 0.95) over the 11-day observation period, with no emetic events in any patient during the acute/chemotherapy phase. Nausea was well-controlled throughout the acute therapy phase (Day 1-6) and increased during the delayed phase (Day 7-11) with a peak mean level of 2.79/10 at Day 10. Aside from lower grade (≤2), headaches, constipation, and diarrhea were the most widely reported adverse effects. Conclusion: The combination of NEPA and dexamethasone is safe and effective for the prevention of CINV in patients receiving BEAM conditioning therapy prior to HCT. The regimen demonstrated greater effectiveness in the acute phase versus the delayed phase, with low levels of nausea throughout the study period and complete emesis prevention during chemotherapy.
OBJECTIVE: This study aimed to determine the prevalence of sarcopenic obesity and its association with the level of physical activity, alone and combined with sedentary behavior.
METHODS: A cross-sectional study was performed. The sample was composed of 317 women aged between 24 and 59 years. Sarcopenic obesity was determined by the coexistence of sarcopenia (reduced muscle mass and strength) and obesity (% fat). Dual-energy x-ray absorption was used to evaluate muscle mass and % fat, with cutoff points of <15 kg and <31.71%, respectively. Strength was assessed by the handgrip test, with a cutoff point of <21.68 kg. Levels of physical activity and sedentary behavior were assessed using the long version of the International Physical Activity Questionnaire. Individuals who did not achieve 150 minutes per week of physical activity were considered insufficiently active. The cutoff point for sedentary behavior was determined based on the 75th percentile (480 min/wk), considering excessive sedentary behavior (≥75th percentile) and low/moderate sedentary behavior (<75th percentile).
RESULTS: The prevalence of sarcopenic obesity was 7.9% (95% CI, 4.9-10.8). Sarcopenic obesity was associated with the general physical activity level (odds ratio, 3.96; 95% CI, 1.32-11.8) and being insufficiently active together with low/moderate sedentary behavior (odds ratio, 4.88; 95% CI, 1.49-16.0).
CONCLUSIONS: There was the presence of sarcopenic obesity in adult women which was associated with the level of general physical activity, alone and combined with sedentary behavior.
A web-based endoscope management system and method for managing, scheduling and tracking in real-time the processing of endoscopy equipment in a single site or across multiple sites. The system allows various useful information relating to the managed endoscopy equipment and its processing history (such as equipment status, equipment movement, equipment repair history, cost and procedural efficiencies, what individuals have processed or come into contact with the equipment) to be tracked and analyzed. The system incorporates a user display and prompt to assist users in following the proper processing and cleaning protocols (preparation, pre-cleaning, automated reprocessing, repair, etc.) for the equipment. The system uses a colour-coded display so that pertinent information can be seen at a glance. This system is used in conjunction with a suitable colour-coded labeling scheme to reduce the possibility that users will process the wrong equipment or improperly store it.
1. Therapy with octreotide acetate can produce severe hypoglycemia in patients with insulinomas. Since pentetreotide is an analog of octreotide, an intravenous line is recommended in any patient suspected of having an insulinoma. An intravenous solution containing glucose should be administered just before and during administration of Indium In 111 Pentetreotide Injection.
  2. The contents of the two vials supplied with the kit are intended only for use in the preparation of Indium In 111 Pentetreotide Injection and are NOT to be administered separately to the patient.
  3. Since indium In 111 pentetreotide is eliminated primarily by renal excretion, use in patients with impaired renal function should be carefully considered.
  4. To help reduce the radiation dose to the thyroid, kidneys, bladder, and other target organs, patients should be well hydrated before the administration of Indium In 111 Pentetreotide Injection. They should increase fluid intake and void frequently for one day after administration of this drug. In addition, it is recommended that patients be given a mild laxative (e.g., bisacodyl or lactulose) before and after administration of Indium In 111 Pentetreotide Injection  (see DOSAGE AND ADMINISTRATION).
  5. Indium In 111 Pentetreotide Injection should be tested for radiolabeling yield of radioactivity prior to administration. The product must be used within 6 hours of preparation.
  6. Components of the kit are sterile and nonpyrogenic. To maintain sterility, it is essential that directions are followed carefully. Aseptic technique must be used during the preparation and administration of Indium In 111 Pentetreotide Injection.
  7. Octreotide acetate and the natural somatostatin hormone may be associated with cholelithiasis, presumably by altering fat absorption and possibly by decreasing motility of the gallbladder. A single dose of Indium In 111 Pentetreotide Injection is not expected to cause cholelithiasis.
  8. As with any other radioactive material, appropriate shielding should be used to avoid unnecessary radiation exposure to the patient, occupational workers, and other persons.
  9. Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides.
In the Phase 2b portion of the study, PET-MF participants received 0.5 mg/kg/d bomedemstat orally qd for 169 days during the ITP. Qualifying participants could continue to receive treatment for an additional 169 days during an ATP as determined by the investigator. The ATP could repeat indefinitely in participants that continued to derive clinical benefit.
This group will receive both the exercise program as well as the nutrition supplement. The components of the exercise program will be same as those of the exercise program alone group. Participants will also be asked to consume two sachets of Ensure NutriVigor every day during the 12-week intervention period. Ensure NutriVigor (one sachet of 54.1 g powder) contains 231 calories, 8.61 g protein, 1.21 g hydroxyl-methyl-butyrate (HMB), 130 IU vitamin D, and 0.29 g omega 3 fatty acid per serving. Participants will be instructed on how to prepare the supplement.